Lenvatinib + Pembrolizumab vs Docetaxel in Stage IV NSCLC – IASLC
International Association for the Study of Lung Cancer – IASLC shared a post on LinkedIn about a recent article by Natasha Leighl et al. published in Journal of Thoracic Oncology:
“In an effort to improve treatment options in advanced pre-treated NSCLC, Leighl et al. studied lenvatinib + pembrolizumab vs docetaxel in patients with stage IV NSCLC the progressed on anti-PD-1/PD-L1 therapy and platinum-containing chemotherapy in the LEAP-008 study.
The combination did not improve efficacy compared to docetaxel – more research is needed to develop more effective therapies.”
Title: LEAP-008: Lenvatinib Plus Pembrolizumab for Metastatic NSCLC That Has Progressed After an Anti–Programmed Cell Death Protein 1 or Anti–Programmed Cell Death Ligand 1 Plus Platinum Chemotherapy
Authors: Natasha Leighl, Luis Paz-Ares, Delvys Rodriguez Abreu, Rina Hui, Sofia Baka, Frédéric Bigot, Makoto Nishio, Alexey Smolin, Samreen Ahmed, Adam Schoenfeld, Sameh Daher, Diego Cortinovis, Vincenzo Di Noia, Helena Linardou, Justin Gainor, Corina Dutcus, Chinyere Okpara, Xuan Deng, Debra Kush, Ashwini Arunachalam, Andrew Song, Byoung Chul Cho
Read the Full Article on Journal of Thoracic Oncology
More posts featuring International Association for the Study of Lung Cancer
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023